Augmentation therapy comparison in refractory obsessive-compulsive disorder with Aripiprazole vs. Risperidone
- Conditions
- Obsessive-compulsive disorder.Obsessive-compulsive disorder
- Registration Number
- IRCT2015110424882N1
- Lead Sponsor
- Kashan University of Medical Sciences, Dr Gholamali Hamidi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Age between 18-60 years;the Yale-Brown obsessive-compulsive scale (Y-BOCS) =16 and suffering from OCD whilst were taken a therapeutic dose of SSRI drugs at least for 12 weeks;negative history of: pregnant or breastfeeding in women; psychotic, bipolar mood, and severe depressive disorders in DSM-IV-TR axis I; any known disorder in DSM-IV-TR axis II like personality disorders or mental retardation; drug and alcohol abuse in the last six months before study; any physical disease impeding the use of Risperidone or Aripiprazole; not psychotherapy during the study.
Exclusion criteria: Any acute or severe physical diseases occurring during the study; more than four weeks loss to follow-up; severe side effects during the study; not using contraceptive methods in females.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of symptoms of OCD. Timepoint: Basline and every 4 weeks. Method of measurement: Y_BOCS.
- Secondary Outcome Measures
Name Time Method nwanted side effects of drugs. Timepoint: Every 4 weeks. Method of measurement: Interview.